Gomes Veloso, Brandão Victor, Mimoso Jorge, Gago Paula, Trigo Joana, Santos Walter, Marques Nuno, Candeias Rui, Pereira Salomé, Marques Vasco, Camacho Ana, de Jesus Ilídio
Department of Cardiology, Faro Hospital, Faro, Portugal.
Rev Port Cardiol. 2012 Mar;31(3):193-201. doi: 10.1016/j.repc.2012.01.013.
To analyze the impact of reperfusion by either primary percutaneous coronary intervention (PPCI) or fibrinolysis, and mortality rates of a pre-hospital fast-track network for treating patients with ST-elevation myocardial infarction (STEMI).
A pre-hospital network for STEMI patients, designated the Green Lane for Acute Myocardial Infarction (GL-AMI), has been implemented in the southern region of Portugal --the Algarve Project. We performed an observational study based on a prospective registry of 1338 patients admitted to Faro Hospital between 2004 and 2009, classified in two groups according to the method of admission: emergency department group (EDG) and GL-AMI group (GLG). More patients from GLG were reperfused (p < 0.0001). PPCI was the preferred method of reperfusion, 73.1% in GLG and 45.3% in EDG. Time delays were significantly shorter in GLG, except for pre-hospital delay: pre-hospital delay (p = 0.11); door-to-needle (p < 0.0001); door-to-balloon (p < 0.0001); and delay between symptoms and reperfusion (p < 0.0001). In-hospital mortality (4.3% vs 9.2%, p = 0.0007) and 6-month mortality (6.3% vs 13.8%, p < 0.0001) were significantly lower in GLG.
The Algarve Project significantly reduced the time delay between onset of symptoms and reperfusion, significantly increased the rate of reperfusion, and significantly reduced in-hospital and six-month mortality.
分析直接经皮冠状动脉介入治疗(PPCI)或溶栓再灌注的影响,以及院前快速通道网络治疗ST段抬高型心肌梗死(STEMI)患者的死亡率。
在葡萄牙南部实施了一个针对STEMI患者的院前网络,即急性心肌梗死绿色通道(GL-AMI)——阿尔加维项目。我们基于对2004年至2009年间入住法鲁医院的1338例患者的前瞻性登记进行了一项观察性研究,根据入院方式将患者分为两组:急诊科组(EDG)和GL-AMI组(GLG)。GLG组有更多患者实现了再灌注(p<0.0001)。PPCI是首选的再灌注方法,GLG组为73.1%,EDG组为45.3%。GLG组的时间延迟明显更短,但院前延迟除外:院前延迟(p = 0.11);门至针时间(p<0.0001);门至球囊时间(p<0.0001);症状出现至再灌注的延迟(p<0.0001)。GLG组的院内死亡率(4.3%对9.2%,p = 0.0007)和6个月死亡率(6.3%对13.8%,p<0.0001)显著更低。
阿尔加维项目显著缩短了症状出现至再灌注的时间延迟,显著提高了再灌注率,并显著降低了院内和6个月死亡率。